Pre-made Lebrikizumab benchmark antibody ( Whole mAb, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-299
Pre-Made Lebrikizumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Lebrikizumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||4i77:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox|
|Conditions Active||Atopic dermatitis|
|Conditions Discontinued||Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis|